Kladrybina: interakcje

Antiviral and antiretroviral drugs: Avoid concomitant use. (etykieta leku Kladrybina, Interakcje z innymi lekami)

Antiviral and antiretroviral drugs: Avoid concomitant use. (etykieta leku Kladrybina, Interakcje z innymi lekami)

Prevention or Management Concomitant use with myelosuppressive or other immunosuppressive drugs is not recommended. (etykieta leku Kladrybina, Interakcje z innymi lekami)

Prevention or Management Concomitant use with myelosuppressive or other immunosuppressive drugs is not recommended. (etykieta leku Kladrybina, Interakcje z innymi lekami)

Prevention or Management Concomitant use with myelosuppressive or other immunosuppressive drugs is not recommended. (etykieta leku Kladrybina, Interakcje z innymi lekami)

Prevention or Management Concomitant use with myelosuppressive or other immunosuppressive drugs is not recommended. (etykieta leku Kladrybina, Interakcje z innymi lekami)

Antiviral and antiretroviral drugs: Avoid concomitant use. (etykieta leku Kladrybina, Interakcje z innymi lekami)

Prevention or Management Concomitant use with myelosuppressive or other immunosuppressive drugs is not recommended. (etykieta leku Kladrybina, Interakcje z innymi lekami)

Prevention or Management Concomitant use with myelosuppressive or other immunosuppressive drugs is not recommended. (etykieta leku Kladrybina, Interakcje z innymi lekami)

Antiviral and antiretroviral drugs: Avoid concomitant use. (etykieta leku Kladrybina, Interakcje z innymi lekami)

Prevention or Management Concomitant use with myelosuppressive or other immunosuppressive drugs is not recommended. (etykieta leku Kladrybina, Interakcje z innymi lekami)

Prevention or Management Avoid co-administration of potent ENT1, CNT3, or BCRP transporter inhibitors (e.g., ritonavir, eltrombopag, curcumin, cyclosporine, dilazep, nifedipine, nimodipine, cilostazol, sulindac, dipyridamole, or reserpine) during the 4 to 5 day MAVENCLAD treatment cycles. (etykieta leku Kladrybina, Interakcje z innymi lekami)

Prevention or Management Avoid co-administration of potent ENT1, CNT3, or BCRP transporter inhibitors (e.g., ritonavir, eltrombopag, curcumin, cyclosporine, dilazep, nifedipine, nimodipine, cilostazol, sulindac, dipyridamole, or reserpine) during the 4 to 5 day MAVENCLAD treatment cycles. (etykieta leku Kladrybina, Interakcje z innymi lekami)

Antiviral and antiretroviral drugs: Avoid concomitant use. (etykieta leku Kladrybina, Interakcje z innymi lekami)

Antiviral and antiretroviral drugs: Avoid concomitant use. (etykieta leku Kladrybina, Interakcje z innymi lekami)

Prevention or Management Avoid co-administration of potent ENT1, CNT3, or BCRP transporter inhibitors (e.g., ritonavir, eltrombopag, curcumin, cyclosporine, dilazep, nifedipine, nimodipine, cilostazol, sulindac, dipyridamole, or reserpine) during the 4 to 5 day MAVENCLAD treatment cycles. (etykieta leku Kladrybina, Interakcje z innymi lekami)

Antiviral and antiretroviral drugs: Avoid concomitant use. (etykieta leku Kladrybina, Interakcje z innymi lekami)

Antiviral and antiretroviral drugs: Avoid concomitant use. (etykieta leku Kladrybina, Interakcje z innymi lekami)

Antiviral and antiretroviral drugs: Avoid concomitant use. (etykieta leku Kladrybina, Interakcje z innymi lekami)

Antiviral and antiretroviral drugs: Avoid concomitant use. (etykieta leku Kladrybina, Interakcje z innymi lekami)

Prevention or Management Avoid co-administration of potent ENT1, CNT3, or BCRP transporter inhibitors (e.g., ritonavir, eltrombopag, curcumin, cyclosporine, dilazep, nifedipine, nimodipine, cilostazol, sulindac, dipyridamole, or reserpine) during the 4 to 5 day MAVENCLAD treatment cycles. (etykieta leku Kladrybina, Interakcje z innymi lekami)

Antiviral and antiretroviral drugs: Avoid concomitant use. (etykieta leku Kladrybina, Interakcje z innymi lekami)

Antiviral and antiretroviral drugs: Avoid concomitant use. (etykieta leku Kladrybina, Interakcje z innymi lekami)

Antiviral and antiretroviral drugs: Avoid concomitant use. (etykieta leku Kladrybina, Interakcje z innymi lekami)

Antiviral and antiretroviral drugs: Avoid concomitant use. (etykieta leku Kladrybina, Interakcje z innymi lekami)

Prevention or Management Concomitant use with myelosuppressive or other immunosuppressive drugs is not recommended. (etykieta leku Kladrybina, Interakcje z innymi lekami)

Antiviral and antiretroviral drugs: Avoid concomitant use. (etykieta leku Kladrybina, Interakcje z innymi lekami)

Prevention or Management Concomitant use with myelosuppressive or other immunosuppressive drugs is not recommended. (etykieta leku Kladrybina, Interakcje z innymi lekami)

Prevention or Management Concomitant use with myelosuppressive or other immunosuppressive drugs is not recommended. (etykieta leku Kladrybina, Interakcje z innymi lekami)

Chicken pox and measles, for example, can have a more serious or even fatal course in children on immunosuppressant corticosteroids. (etykieta leku Fludrokortyzon, Ostrzeżenia)

Persons who are on immunosuppressant doses of corticosteroids should be warned to avoid exposure to chickenpox or measles. (etykieta leku Flunizolid, Środki ostrożności)

Antiviral and antiretroviral drugs: Avoid concomitant use. (etykieta leku Kladrybina, Interakcje z innymi lekami)

Prevention or Management Concomitant use with myelosuppressive or other immunosuppressive drugs is not recommended. (etykieta leku Kladrybina, Interakcje z innymi lekami)

Prevention or Management Concomitant use with myelosuppressive or other immunosuppressive drugs is not recommended. (etykieta leku Kladrybina, Interakcje z innymi lekami)

Prevention or Management Concomitant use with myelosuppressive or other immunosuppressive drugs is not recommended. (etykieta leku Kladrybina, Interakcje z innymi lekami)

Immunosuppressants Everolimus Sirolimus Temsirolimus (IV) Not recommended during and 2 weeks after TOLSURA treatment. (etykieta leku Itrakonazol, Interakcje z innymi lekami)

Antiviral and antiretroviral drugs: Avoid concomitant use. (etykieta leku Kladrybina, Interakcje z innymi lekami)

About 13 percent of the cases of neutropenia have ended fatally, but almost all fatalities were in patients with serious illness, having collagen vascular disease, renal failure, heart failure or immunosuppressant therapy, or a combination of these complicating factors. (etykieta leku Kaptopryl, Ostrzeżenia)

Prevention or Management Avoid co-administration of potent ENT1, CNT3, or BCRP transporter inhibitors (e.g., ritonavir, eltrombopag, curcumin, cyclosporine, dilazep, nifedipine, nimodipine, cilostazol, sulindac, dipyridamole, or reserpine) during the 4 to 5 day MAVENCLAD treatment cycles. (etykieta leku Kladrybina, Interakcje z innymi lekami)

Prevention or Management Avoid co-administration of potent ENT1, CNT3, or BCRP transporter inhibitors (e.g., ritonavir, eltrombopag, curcumin, cyclosporine, dilazep, nifedipine, nimodipine, cilostazol, sulindac, dipyridamole, or reserpine) during the 4 to 5 day MAVENCLAD treatment cycles. (etykieta leku Kladrybina, Interakcje z innymi lekami)

Antiviral and antiretroviral drugs: Avoid concomitant use. (etykieta leku Kladrybina, Interakcje z innymi lekami)

Antiviral and antiretroviral drugs: Avoid concomitant use. (etykieta leku Kladrybina, Interakcje z innymi lekami)

Prevention or Management Concomitant use with myelosuppressive or other immunosuppressive drugs is not recommended. (etykieta leku Kladrybina, Interakcje z innymi lekami)

Antiviral and antiretroviral drugs: Avoid concomitant use. (etykieta leku Kladrybina, Interakcje z innymi lekami)

Prevention or Management Avoid co-administration of potent ENT1, CNT3, or BCRP transporter inhibitors (e.g., ritonavir, eltrombopag, curcumin, cyclosporine, dilazep, nifedipine, nimodipine, cilostazol, sulindac, dipyridamole, or reserpine) during the 4 to 5 day MAVENCLAD treatment cycles. (etykieta leku Kladrybina, Interakcje z innymi lekami)

Antiviral and antiretroviral drugs: Avoid concomitant use. (etykieta leku Kladrybina, Interakcje z innymi lekami)

Prevention or Management Concomitant use with myelosuppressive or other immunosuppressive drugs is not recommended. (etykieta leku Kladrybina, Interakcje z innymi lekami)

Prevention or Management Concomitant use with myelosuppressive or other immunosuppressive drugs is not recommended. (etykieta leku Kladrybina, Interakcje z innymi lekami)

Prevention or Management Concomitant use with myelosuppressive or other immunosuppressive drugs is not recommended. (etykieta leku Kladrybina, Interakcje z innymi lekami)

Prevention or Management Concomitant use with myelosuppressive or other immunosuppressive drugs is not recommended. (etykieta leku Kladrybina, Interakcje z innymi lekami)

Antiviral and antiretroviral drugs: Avoid concomitant use. (etykieta leku Kladrybina, Interakcje z innymi lekami)

Prevention or Management Avoid co-administration of potent ENT1, CNT3, or BCRP transporter inhibitors (e.g., ritonavir, eltrombopag, curcumin, cyclosporine, dilazep, nifedipine, nimodipine, cilostazol, sulindac, dipyridamole, or reserpine) during the 4 to 5 day MAVENCLAD treatment cycles. (etykieta leku Kladrybina, Interakcje z innymi lekami)

Prevention or Management Avoid co-administration of potent ENT1, CNT3, or BCRP transporter inhibitors (e.g., ritonavir, eltrombopag, curcumin, cyclosporine, dilazep, nifedipine, nimodipine, cilostazol, sulindac, dipyridamole, or reserpine) during the 4 to 5 day MAVENCLAD treatment cycles. (etykieta leku Kladrybina, Interakcje z innymi lekami)

Prevention or Management Avoid co-administration of potent ENT1, CNT3, or BCRP transporter inhibitors (e.g., ritonavir, eltrombopag, curcumin, cyclosporine, dilazep, nifedipine, nimodipine, cilostazol, sulindac, dipyridamole, or reserpine) during the 4 to 5 day MAVENCLAD treatment cycles. (etykieta leku Kladrybina, Interakcje z innymi lekami)

Prevention or Management Concomitant use with myelosuppressive or other immunosuppressive drugs is not recommended. (etykieta leku Kladrybina, Interakcje z innymi lekami)

Prevention or Management Concomitant use with myelosuppressive or other immunosuppressive drugs is not recommended. (etykieta leku Kladrybina, Interakcje z innymi lekami)

Prevention or Management Concomitant use with myelosuppressive or other immunosuppressive drugs is not recommended. (etykieta leku Kladrybina, Interakcje z innymi lekami)

Antiviral and antiretroviral drugs: Avoid concomitant use. (etykieta leku Kladrybina, Interakcje z innymi lekami)

Antiviral and antiretroviral drugs: Avoid concomitant use. (etykieta leku Kladrybina, Interakcje z innymi lekami)

Prevention or Management Concomitant use with myelosuppressive or other immunosuppressive drugs is not recommended. (etykieta leku Kladrybina, Interakcje z innymi lekami)

Prevention or Management Avoid co-administration of potent ENT1, CNT3, or BCRP transporter inhibitors (e.g., ritonavir, eltrombopag, curcumin, cyclosporine, dilazep, nifedipine, nimodipine, cilostazol, sulindac, dipyridamole, or reserpine) during the 4 to 5 day MAVENCLAD treatment cycles. (etykieta leku Kladrybina, Interakcje z innymi lekami)

Prevention or Management Concomitant use with myelosuppressive or other immunosuppressive drugs is not recommended. (etykieta leku Kladrybina, Interakcje z innymi lekami)

Prevention or Management Concomitant use with myelosuppressive or other immunosuppressive drugs is not recommended. (etykieta leku Kladrybina, Interakcje z innymi lekami)

Prevention or Management Avoid co-administration of potent ENT1, CNT3, or BCRP transporter inhibitors (e.g., ritonavir, eltrombopag, curcumin, cyclosporine, dilazep, nifedipine, nimodipine, cilostazol, sulindac, dipyridamole, or reserpine) during the 4 to 5 day MAVENCLAD treatment cycles. (etykieta leku Kladrybina, Interakcje z innymi lekami)

Prevention or Management Concomitant use with myelosuppressive or other immunosuppressive drugs is not recommended. (etykieta leku Kladrybina, Interakcje z innymi lekami)

Prevention or Management Concomitant use with myelosuppressive or other immunosuppressive drugs is not recommended. (etykieta leku Kladrybina, Interakcje z innymi lekami)

Antiviral and antiretroviral drugs: Avoid concomitant use. (etykieta leku Kladrybina, Interakcje z innymi lekami)

Prevention or Management Concomitant use with myelosuppressive or other immunosuppressive drugs is not recommended. (etykieta leku Kladrybina, Interakcje z innymi lekami)

Prevention or Management Concomitant use with myelosuppressive or other immunosuppressive drugs is not recommended. (etykieta leku Kladrybina, Interakcje z innymi lekami)

Prevention or Management Concomitant use with myelosuppressive or other immunosuppressive drugs is not recommended. (etykieta leku Kladrybina, Interakcje z innymi lekami)

Prevention or Management Concomitant use with myelosuppressive or other immunosuppressive drugs is not recommended. (etykieta leku Kladrybina, Interakcje z innymi lekami)

Prevention or Management Concomitant use with myelosuppressive or other immunosuppressive drugs is not recommended. (etykieta leku Kladrybina, Interakcje z innymi lekami)

Antiviral and antiretroviral drugs: Avoid concomitant use. (etykieta leku Kladrybina, Interakcje z innymi lekami)

Immunosuppressants Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (etykieta leku Amlodypina, Interakcje z innymi lekami)

Impact of Amlodipine on Other Drugs Immunosuppressants Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (etykieta leku Amlodypina + atorwastatyna, Interakcje z innymi lekami)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (etykieta leku Amlodypina + olmesartan, Interakcje z innymi lekami)

Immunosuppressants Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when coadministered. (etykieta leku Amlodypina + walsartan, Interakcje z innymi lekami)

Prevention or Management Consider a possible decrease in cladribine efficacy if potent BCRP (e.g., corticosteroids) or P-gp (e.g., rifampicin, St. (etykieta leku Kladrybina, Interakcje z innymi lekami)

Prevention or Management Consider a possible decrease in cladribine efficacy if potent BCRP (e.g., corticosteroids) or P-gp (e.g., rifampicin, St. (etykieta leku Kladrybina, Interakcje z innymi lekami)

Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. (etykieta leku Bendamustyna, Ostrzeżenia i środki ostrożności)

Prevention or Management Consider a possible decrease in cladribine efficacy if potent BCRP (e.g., corticosteroids) or P-gp (e.g., rifampicin, St. (etykieta leku Kladrybina, Interakcje z innymi lekami)

Prevention or Management Consider a possible decrease in cladribine efficacy if potent BCRP (e.g., corticosteroids) or P-gp (e.g., rifampicin, St. (etykieta leku Kladrybina, Interakcje z innymi lekami)

Prevention or Management Consider a possible decrease in cladribine efficacy if potent BCRP (e.g., corticosteroids) or P-gp (e.g., rifampicin, St. (etykieta leku Kladrybina, Interakcje z innymi lekami)

Prevention or Management Consider a possible decrease in cladribine efficacy if potent BCRP (e.g., corticosteroids) or P-gp (e.g., rifampicin, St. (etykieta leku Kladrybina, Interakcje z innymi lekami)

Prevention or Management Consider a possible decrease in cladribine efficacy if potent BCRP (e.g., corticosteroids) or P-gp (e.g., rifampicin, St. (etykieta leku Kladrybina, Interakcje z innymi lekami)

Prevention or Management Consider a possible decrease in cladribine efficacy if potent BCRP (e.g., corticosteroids) or P-gp (e.g., rifampicin, St. (etykieta leku Kladrybina, Interakcje z innymi lekami)

Other risk factors for the development of ONJ include immunosuppressive therapy, treatment with angiogenesis inhibitors, systemic corticosteroids, diabetes, and gingival infections. (etykieta leku Denosumab, Ostrzeżenia i środki ostrożności)

Prevention or Management Consider a possible decrease in cladribine efficacy if potent BCRP (e.g., corticosteroids) or P-gp (e.g., rifampicin, St. (etykieta leku Kladrybina, Interakcje z innymi lekami)

Immunosuppressants Clinical Impact: Immunosuppressants such as cyclosporine and tacrolimus can produce nephrotoxicity with decreases in creatinine clearance and rises in serum creatinine, and because renal excretion is the primary elimination route of fibrate drugs including fenofibrate, there is a risk that an interaction will lead to deterioration of renal… (etykieta leku Fenofibrat, Interakcje z innymi lekami)

Prevention or Management Consider a possible decrease in cladribine efficacy if potent BCRP (e.g., corticosteroids) or P-gp (e.g., rifampicin, St. (etykieta leku Kladrybina, Interakcje z innymi lekami)

Prevention or Management Consider a possible decrease in cladribine efficacy if potent BCRP (e.g., corticosteroids) or P-gp (e.g., rifampicin, St. (etykieta leku Kladrybina, Interakcje z innymi lekami)

Prevention or Management Consider a possible decrease in cladribine efficacy if potent BCRP (e.g., corticosteroids) or P-gp (e.g., rifampicin, St. (etykieta leku Kladrybina, Interakcje z innymi lekami)

Prevention or Management Consider a possible decrease in cladribine efficacy if potent BCRP (e.g., corticosteroids) or P-gp (e.g., rifampicin, St. (etykieta leku Kladrybina, Interakcje z innymi lekami)

Prevention or Management Consider a possible decrease in cladribine efficacy if potent BCRP (e.g., corticosteroids) or P-gp (e.g., rifampicin, St. (etykieta leku Kladrybina, Interakcje z innymi lekami)

Immunosuppressants everolimus, rapamycin (also known as sirolimus), temsirolimus budesonide, ciclesonide, cyclosporine, dexamethasone, fluticasone, methylprednisolone, tacrolimus Rapamycin (sirolimus): Ketoconazole tablets 200 mg daily for 10 days increased the C max and AUC of a single 5 mg dose of sirolimus by 4.3 fold and 10.9 fold, respectively in 23 healthy… (etykieta leku Ketokonazol, Interakcje z innymi lekami)

Prevention or Management Consider a possible decrease in cladribine efficacy if potent BCRP (e.g., corticosteroids) or P-gp (e.g., rifampicin, St. (etykieta leku Kladrybina, Interakcje z innymi lekami)

Frequent PT/INR determinations are advisable until it has been definitely determined that the PT/INR has stabilized Immunosuppressants Clinical Impact: Immunosuppressants such as cyclosporine and tacrolimus can produce nephrotoxicity with decreases in creatinine clearance and rises in serum creatinine, and because renal excretion is the primary elimination route… (etykieta leku Kwas fenofibrowy, Interakcje z innymi lekami)

HBV reactivation has also been reported in patients receiving certain immunosuppressants or chemotherapeutic agents; the risk of HBV reactivation associated with treatment with HCV direct-acting antivirals may be increased in these patients. (etykieta leku Ledipaswir + sofosbuwir, Ostrzeżenia i środki ostrożności)

Prevention or Management Consider a possible decrease in cladribine efficacy if potent BCRP (e.g., corticosteroids) or P-gp (e.g., rifampicin, St. (etykieta leku Kladrybina, Interakcje z innymi lekami)

Prevention or Management Consider a possible decrease in cladribine efficacy if potent BCRP (e.g., corticosteroids) or P-gp (e.g., rifampicin, St. (etykieta leku Kladrybina, Interakcje z innymi lekami)

Immunosuppressive Agents There have been reports of increased blood concentrations of cyclosporine and tacrolimus into toxic ranges when patients received these drugs concomitantly with nefazodone. (etykieta leku Nefazodon, Interakcje z innymi lekami)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (etykieta leku Olmesartan + amlodypina + hydrochlorotiazyd, Interakcje z innymi lekami)

Prevention or Management Consider a possible decrease in cladribine efficacy if potent BCRP (e.g., corticosteroids) or P-gp (e.g., rifampicin, St. (etykieta leku Kladrybina, Interakcje z innymi lekami)

Treatment has consisted of high doses of corticosteroids alone or, in some cases, concomitantly with an immunosuppressant. (etykieta leku Penicylamina, Ostrzeżenia)

Prevention or Management Consider a possible decrease in cladribine efficacy if potent BCRP (e.g., corticosteroids) or P-gp (e.g., rifampicin, St. (etykieta leku Kladrybina, Interakcje z innymi lekami)

Prevention or Management Consider a possible decrease in cladribine efficacy if potent BCRP (e.g., corticosteroids) or P-gp (e.g., rifampicin, St. (etykieta leku Kladrybina, Interakcje z innymi lekami)

Glipizide Decrease exposure Immunosuppressive Agents Cyclosporine Decrease exposure Tacrolimus Prevention or Management: Monitoring of whole blood concentrations and appropriate dosage adjustments of tacrolimus are recommended when rifampin and tacrolimus are used concomitantly. (etykieta leku Ryfampicyna, Interakcje z innymi lekami)

…Digoxin Corticosteroids Prednisone Fibrates Clofibrate Oral Hypoglycemics Sulfonylureas (e.g., glyburide, glipizide) Hormonal Contraceptives/Progestins Ethinyl estradiol, levonorgestrel Immunosuppressants Cyclosporine, tacrolimus Methylxanthines Theophylline Narcotic analgesics Methadone Phosphodiesterase-5 (PDE-5) Inhibitors Sildenafil Thyroid preparations Levothyroxine… (etykieta leku Ryfapentyna, Interakcje z innymi lekami)

HBV reactivation has also been reported in patients receiving certain immunosuppressant or chemotherapeutic agents; the risk of HBV reactivation associated with treatment with HCV direct-acting antivirals may be increased in these patients. (etykieta leku Sofosbuwir + welpataswir, Ostrzeżenia i środki ostrożności)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (etykieta leku Telmisartan + amlodypina, Interakcje z innymi lekami)

Prophylaxis of PJP should be considered when concomitant use of corticosteroids or other immunosuppressive agents are required. (etykieta leku Temsyrolimus, Ostrzeżenia i środki ostrożności)

Prevention or Management Consider a possible decrease in cladribine efficacy if potent BCRP (e.g., corticosteroids) or P-gp (e.g., rifampicin, St. (etykieta leku Kladrybina, Interakcje z innymi lekami)

Cyclosporine, tacrolimus: Monitor for toxicities of these immunosuppressive drugs ( 7.1 ) (etykieta leku Tynidazol, Interakcje z innymi lekami)

Thirty-four patients were treated with corticosteroids and one patient was treated with a non-steroidal immunosuppressant. (etykieta leku Aksytynib, Ostrzeżenia i środki ostrożności)

IMNM is characterized by proximal muscle weakness and elevated serum creatine kinase that persists despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy; and improvement with immunosuppressive agents. (etykieta leku Atorwastatyna, Ostrzeżenia i środki ostrożności)

Prevention or Management Avoid co-administration of potent ENT1, CNT3, or BCRP transporter inhibitors (e.g., ritonavir, eltrombopag, curcumin, cyclosporine, dilazep, nifedipine, nimodipine, cilostazol, sulindac, dipyridamole, or reserpine) during the 4 to 5 day MAVENCLAD treatment cycles. (etykieta leku Kladrybina, Interakcje z innymi lekami)

IMNM is characterized by proximal muscle weakness and elevated serum creatine kinase that persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy without significant inflammation; and improvement with immunosuppressive agents. (etykieta leku Ezetymib + symwastatyna, Ostrzeżenia i środki ostrożności)

IMNM is characterized by proximal muscle weakness and elevated serum CK, which persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody, muscle biopsy showing necrotizing myopathy, and improvement with immunosuppressive agents. (etykieta leku Fluwastatyna, Ostrzeżenia i środki ostrożności)

IMNM is characterized by: proximal muscle weakness and elevated serum creatine kinase, which persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy; and improvement with immunosuppressive agents. (etykieta leku Lowastatyna, Ostrzeżenia)

IMNM is characterized by proximal muscle weakness and elevated serum creatine kinase that persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy; and improvement with immunosuppressive agents. (etykieta leku Pitawastatyna, Ostrzeżenia i środki ostrożności)

CYP3A Substrates Immunosuppressants that are CYP3A4 Substrates Mechanism and Clinical Effect(s) Posaconazole is a strong CYP3A4 inhibitor. (etykieta leku Pozakonazol, Interakcje z innymi lekami)

IMNM is characterized by proximal muscle weakness and elevated serum creatine kinase that persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy; and improvement with immunosuppressive agents. (etykieta leku Prawastatyna, Ostrzeżenia i środki ostrożności)

In some cases, vasculitis resolved/improved with drug discontinuation; however, more severe cases required treatment with additional measures including corticosteroids, immunosuppressant therapy, and plasmapheresis. (etykieta leku Propylotiouracyl, Ostrzeżenia)

IMNM is characterized by proximal muscle weakness and elevated serum creatine kinase that persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy; and improvement with immunosuppressive agents. (etykieta leku Rozuwastatyna, Ostrzeżenia i środki ostrożności)

Antiviral and Antiretroviral Drugs Clinical Impact Compounds that require intracellular phosphorylation to become active (e.g., lamivudine, zalcitabine, ribavirin, stavudine, and zidovudine) could interfere with the intracellular phosphorylation and activity of cladribine. (etykieta leku Kladrybina, Interakcje z innymi lekami)

IMNM is characterized by proximal muscle weakness and elevated serum creatine kinase that persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy without significant inflammation; and improvement with immunosuppressive agents. (etykieta leku Symwastatyna, Ostrzeżenia i środki ostrożności)

Prevention or Management Avoid co-administration of potent ENT1, CNT3, or BCRP transporter inhibitors (e.g., ritonavir, eltrombopag, curcumin, cyclosporine, dilazep, nifedipine, nimodipine, cilostazol, sulindac, dipyridamole, or reserpine) during the 4 to 5 day MAVENCLAD treatment cycles. (etykieta leku Kladrybina, Interakcje z innymi lekami)

In some cases, vasculitis resolved/improved with drug discontinuation; however, more severe cases required treatment with additional measures including corticosteroids, immunosuppressant therapy, and plasmapheresis. (etykieta leku Tiamazol, Ostrzeżenia)

Prevention or Management Avoid co-administration of potent ENT1, CNT3, or BCRP transporter inhibitors (e.g., ritonavir, eltrombopag, curcumin, cyclosporine, dilazep, nifedipine, nimodipine, cilostazol, sulindac, dipyridamole, or reserpine) during the 4 to 5 day MAVENCLAD treatment cycles. (etykieta leku Kladrybina, Interakcje z innymi lekami)

…Repaglinide, Rosiglitazone: [See Warnings and Precautions ( 5.4 ) and Adverse Reactions ( 6.2 )] Insulin Insulin: [See Warnings and Precautions ( 5.4 ) and Adverse Reactions ( 6.2 )] Immunosuppressants: Cyclosporine Use With Caution Cyclosporine: There have been spontaneous or published reports of CYP3A based interactions of clarithromycin with cyclosporine. (etykieta leku Klarytromycyna, Interakcje z innymi lekami)